Sorrentino_Andrea

Andrea Sorrentino

Sorrentino_Andrea

Andrea Sorrentino

Partner

New York + 1 212 937 7288

Andrea Sorrentino's practice focuses on all aspects of corporate law. She represents public and private companies, as well as investment banks and other financial institutions acting as underwriters, in a variety of industries, including technology, life sciences and financial services. Ms. Sorrentino has represented clients on a wide range of capital markets and financing transactions, including venture financings, initial public offerings, follow-on equity offerings, registered direct offerings, private placements, debt offerings and at-the-market (ATM) programs. She regularly advises public companies on securities law compliance, ongoing disclosure requirements, SEC reporting obligations and corporate governance matters.

Experience

  • Capital Markets

    • Schrödinger in its initial public offering and subsequent follow-on public offering of approximately $579 million
    • Inozyme Pharma in its $128.8 million initial public offering, its $73.1 million follow-on offering and its $69 million follow-on offering
    • Fulcrum Therapeutics in its $72 million initial public offering, its $68.5 million private placement, its $50.6 million follow-on offering and its $144.2 million follow-on offering
    • Cue Health in its $200 million initial public offering
    • Nuvalent in its $281.6 million follow-on public offering 
    • Solid Biosciences in its $200 million follow-on public offering and its $240 million private placement
    • Verve Therapeutics in its $225 million and $125 million follow-on public offerings
    • Ocular Therapeutix in its $115 million follow-on public offering and its $325 million private placement
    • PTC Therapeutics in its $550 million convertible notes offering
    • Astria Therapeutics in its $125 million underwritten registered direct offering
    • Xilio Therapeutics in its $50 million public offering
    • Underwriters in Q32 Bio’s $200 million follow-on public offering and $55 million private placement
    • Underwriters in Celldex Therapeutics’ $345 million follow-on public offering
    • Underwriters in Disc Medicine’s $287.5 million follow-on public offering
    • Underwriters in Viridian’s $254 million follow-on public offering
    • Curis in its $15.1 million registered direct offering
    • Casella Waste Systems in its $517.5 million follow-on public offering 
    • KALA BIO in its $134 million public offering and its $10.75 million private placement
    • Numerous ATM offerings for clients

  • Venture Capital

    • Schrödinger in its $110 million Series E financing
    • Ratio Therapeutics in its $70 million Series C financing
    • PAQ Therapeutics in its $77 million Series B financing
    • Ribon Therapeutics in its $65 million Series B financing
    • Inozyme Pharma in its $67 million Series A-2 financing
    • Fulcrum Therapeutics in its $80 million Series B financing
    • Pandion Therapeutics in its $58 million Series A financing
    • Sonde Health in its $19.25 million Series B financing 
    • Tvardi Therapeutics in its $9 million Series A financing
    • Immuta in its $100 million Series E financing and its $90 million Series D financing
    • Forbion Capital Partners and other funds in venture and strategic financings

Recognition

  • Selected for inclusion in Best Lawyers: Ones to Watch for corporate law (2023–2025) and corporate governance and compliance law (2024–2025)
  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021 and 2022 in the area of corporate law

Insights & News

View all of Andrea's insights & news

Credentials

  • Education

    • JD, Boston University School of Law, 2015

      magna cum laude

      Editor, Boston University Law Review, Edward F. Hennessey Distinguished Scholar

    • BA, Political Science, Boston University, 2011

      summa cum laude

  • Admissions

    • New York

    • Massachusetts

Credentials

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel